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2 
Abstract 22 
This guideline will inform physicians, nurses, dieticians, pharmacists, caregivers and other home 23 
parenteral nutrition (HPN) providers, as well as healthcare administrators and policy makers, 24 
about appropriate and safe HPN provision. This guideline will also inform patients requiring HPN. 25 
The guideline is based on previous published guidelines and provides an update of current 26 
evidence and expert opinion; it consists of 71 recommendations that address the indications for 27 
HPN, central venous access device (CVAD) and infusion pump, infusion catheter and CVAD site 28 
care, nutritional admixtures, program monitoring and management. Meta-analyses, systematic 29 
reviews and single clinical trials based on clinical questions were searched according to the PICO 30 
format. The evidence was evaluated and used to develop clinical recommendations implementing 31 
Scottish Intercollegiate Guidelines Network methodology. The guideline was commissioned and 32 
financially supported by ESPEN and members of the guideline group were selected by ESPEN. 33 
Keywords 34 
Caregiver, Central venous access device, Home parenteral nutrition, Intestinal failure, 35 
Management, Monitoring, Multidisciplinary team, Parenteral nutrition admixture, Patient training 36 
List of abbreviations 37 
AIO, all-in-one parenteral nutrition admixture; CDC, Centers for Disease Control and Prevention;  38 
CIF, chronic intestinal failure; CRBSI, catheter-related bloodstream infection; CVAD, central venous 39 
access device; CVC, central venous catheter; EN, enteral nutrition; HPN, home parenteral 40 
nutrition; IF, intestinal failure; NST, nutrition support team; PICC, peripherally inserted central 41 
venous catheter; PN, parenteral nutrition; QoL, quality of life; RCT, randomized controlled trial 42 
43 
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Introduction 44 
Parenteral nutrition (PN) is a type of medical nutrition therapy provided through the intravenous 45 
administration of nutrients such as amino acids, glucose, lipids, electrolytes, vitamins and trace 46 
elements [1]. It is categorized as total (or exclusive) PN, where it meets the patient's nutritional 47 
needs in entirety, and as supplemental (partial or complementary) PN, where nutrition is also 48 
provided via the oral or enteral route [1]. PN can be administered either in, or outside, the 49 
hospital setting; the latter defined as home parenteral nutrition (HPN) [1]. 50 
HPN is the primary life-saving therapy for patients with chronic intestinal failure (CIF) due to either 51 
benign (absence of malignant disease) or malignant diseases [2-4]. HPN may also be provided as 52 
palliative nutrition to patients in late phases of end-stage diseases [1]. As HPN is sometimes used 53 
to prevent or treat malnutrition in patients with a functioning intestine, who decline medical 54 
nutrition via the oral/enteral route, HPN and CIF cannot be considered synonymous [2]. Thus, on 55 
the basis of underlying gastrointestinal function and disease, in tandem with patient 56 
characteristics, four clinical scenarios for the use of HPN can be identified [2-4]: HPN as primary 57 
life-saving therapy for a patient with CIF due to benign disease; HPN for CIF due to  malignant 58 
diseases, often transiently occurring during curative treatments; HPN included in a program of 59 
palliative care for incurable malignant disease, to avoid death from malnutrition; HPN used to 60 
prevent or treat malnutrition in patients with a functioning intestine, who decline other types of 61 
medical nutrition (‘no-CIF scenario’). The goal and characteristics of the HPN program, as well as 62 
the specific needs of the patient, may differ among the four clinical scenarios (Table 1). 63 
The first European Society for Clinical Nutrition and Metabolism (ESPEN) guideline on HPN was 64 
published in 2009 [3]. It consisted of 26 recommendations, 10 were based on some evidence 65 
(grade B recommendations) but 16 were mostly based on expert opinion (‘grade C 66 
recommendations’) [3]. In 2016, ESPEN guidelines for CIF due to benign disease was published, 67 
4 
including 11 recommendations on HPN management, 17 on PN formulation and 22 on the 68 
prevention and treatment of central venous catheter (CVC)-related complications. [4]. The grade 69 
of evidence was very low for 31 recommendations, low for 14, moderate for 3 and high for 2, 70 
whereas the strength of the recommendations was weak for 18 and strong for 32 [4]. Most of the 71 
recommendations from both guidelines are still valid, particularly those covering nutritional 72 
requirements, metabolic complications and central venous access device (CVAD) management. 73 
Other guidelines and standards for HPN have also been provided by scientific societies and 74 
government bodies [5-15]; however, a systematic review revealed substantial differences among 75 
the recommendations published [10]. Furthermore, the management and provision of HPN differs 76 
among countries and among HPN centers within countries [16,17], although HPN provision by 77 
different programs should be homogeneous in order to ensure equity of patient access to an 78 
appropriate and safe HPN service.  79 
Thus, an updated version of ESPEN guidelines on HPN care was commissioned in order to 80 
incorporate new evidence since the publication of the previous ESPEN guidelines, as well as to 81 
highlight recommendations on safe HPN administration and also to include the patient’s 82 
perspective. 83 
Table 1. Aims of the HPN program, intravenous supplementation and patient care requirements, 84 
categorized according to the clinical scenarios based on the underlying clinical condition. 85 
HPN program and 
patient care requirement 
Benign CIF scenario Malignant scenarios No CIF scenario 
Aim (additional to 
avoiding death from 
malnutrition) 
Social, employment & 
familial rehabilitation; 
improved quality of life; 
intestinal rehabilitation 
• Treatment of CIF due to 
ongoing oncological 
therapy or to 
gastrointestinal 
obstruction 
• Palliative care 
Alternative to other 
potentially effective 
modalities of nutritional 
support (e.g. enteral) 
refused by the patient. 
Expected duration Temporary or permanent 
(life-long) 
 
Mostly temporary: 
• Short <6 months 
Temporary or permanent 
 
5 
• Long: >6 months 
Intravenous 
supplementation 
requirements  
Supplemental or total;  
high fluid volume and 
electrolyte contents often 
required 
CIF: mostly supplemental, 
but can be total; mostly 
normal volume (high volume 
may be required in GI 
obstruction) 
Palliative: mostly total; 
normal/low volume 
Mostly supplemental with 
normal volume 
Type of PN admixture 
more frequently required  
“Tailored” or 
“customized” 
(compounded), requiring 
refrigeration 
“Premade” or “premixed” 
(ready-to-use) 
“Premade” or “premixed” 
(ready-to-use) 
Patient mobility and 
dependency on caregiver 
Mostly ambulatory and 
independent (depending 
on age and co-morbidity). 
Travelling for work and 
holidays often required 
CIF: ambulatory or 
housebound, mostly 
dependent 
Palliative: housebound, from 
bed to chair, dependent 
Ambulatory, or housebound 
(neurological disorders), 
sometimes dependent 
Patient homecare nurse 
assistance requirement 
Rare; depending on age 
and co-morbidity 
Frequent Sometimes 
CIF, chronic intestinal failure; HPN, home parenteral nutrition; PN, parenteral nutrition 86 
 87 
Aim 88 
The aim of the present guideline is to provide recommendations for the appropriate and safe 89 
provision of HPN. This guideline does not include recommendations for the patient’s nutrient 90 
requirements in specific conditions, for which the reader can refer to previous ESPEN guidelines 91 
[3,4,15]. 92 
93 
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Methods 94 
The present guideline was developed according to the standard operating procedure for ESPEN 95 
guidelines [18]. It is an update of previous guidelines [3-15]. The guideline was developed by an 96 
expert group from seven European countries, representing different professions including eight 97 
physicians (LP, FB, FJ, SK, SL, AVG, GW, SCB), a pharmacist (SM), a nurse (KB) and two patient 98 
representatives (ML, CW).  99 
Methodology of guideline development 100 
Based on the standard operating procedures for ESPEN guidelines and consensus papers, the first 101 
step of the guideline development was the formulation of so-called PICO questions, which address 102 
specific patient groups or problems, interventions, compares different therapies and are outcome-103 
related [18]. In total, 17 PICO questions were created and were split into six main chapters, 104 
“indications for HPN”, “central venous access device (CVAD) and infusion pump”, “infusion line 105 
and CVAD site care”, “nutritional admixtures”, “program monitoring” and “management”.  106 
The PICO questions for the different topics were allocated to subgroups/experts who reviewed the 107 
previous guidelines and standards [3-15] and performed a literature search to identify suitable 108 
meta-analyses, systematic reviews and primary studies (for details see “search strategy” below). A 109 
total of 71 recommendations were formulated to answer the PICO questions. The grading system 110 
of the Scottish Intercollegiate Guidelines Network (SIGN) was used to grade the literature [19]. 111 
Allocation of studies to the different levels of evidence is shown in Table 2. The working group 112 
added commentaries to the recommendations detailing the basis of the recommendations made. 113 
 114 
 115 
 116 
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Table 2. Levels of evidence 117 
1++  High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 
1+  Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 
1-  Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++  High quality systematic reviews of case control or cohort or studies. High quality case control or 
cohort studies with a very low risk of confounding or bias and a high probability that the relationship 
is causal 
2+  Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate 
probability that the relationship is causal 
2-  Case control or cohort studies with a high risk of confounding or bias and a significant risk that the 
relationship is not causal 
3  Non-analytic studies, e.g. case reports, case series 
4  Expert opinion 
According to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Source: SIGN 50: A guideline 118 
developer’s handbook. Quick reference guide October 2014 [19] 119 
 120 
Recommendations were graded according to the levels of evidence available (see Table 3). In 121 
some cases, a downgrading was necessary, for example, due to the lack of quality of primary 122 
studies included in a meta-analysis. The wording of the recommendations reflects the grades of 123 
recommendations; level A is indicated by “shall”, level B by “should” and level 0 by “can/may”. A 124 
good practice point (GPP) is based on experts’ opinions due to the lack of studies; in this situation, 125 
the choice of wording was not restricted.  126 
Table 3. Grades of recommendation [18] 127 
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the 
target population; or  
A body of evidence consisting principally of studies rated as 1+, directly applicable to the target 
population, and demonstrating overall consistency of results 
B A body of evidence including studies rated as 2++, directly applicable to the target population; or 
A body of evidence including studies rated as 2+, directly applicable to the target population and 
demonstrating overall consistency of results; or 
and demonstrating overall consistency of results; or 
Extrapolated evidence from studies rated as 1++ or 1+ 
0 Evidence level 3 or 4; or 
Extrapolated evidence from studies rated as 2++ or 2+ 
GPP Good practice points/expert consensus: Recommended best practice based on the clinical 
experience of the guideline development group 
 128 
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Between February 21
th
 and March 25
th
 2019, online voting on the recommendations was 129 
undertaken using the “guideline-services.com” platform. All ESPEN members were invited to agree 130 
or disagree with, and to comment upon, each of the original 72 recommendations and 7 131 
statements generated by the guideline committee. A first draft of the guidelines was also made 132 
available to participants at the same time. 61 recommendations and 5  statements reached an 133 
agreement of >90 %, 10 recommendations reached an agreement of >75 – 90 % and 2 statements 134 
reached an of agreement ≤75 %. Those recommendations/statements with an agreement >90 % 135 
(i.e. those with a strong consensus) were directly passed, while all others were revised according 136 
to the comments made and then voted on again during a consensus conference which took place 137 
in Frankfurt on April 29
th
 2019. Apart from one, all recommendations received an agreement of 138 
>90 %. Two former statements were transformed into recommendations, both with >90% 139 
agreement. Three of the original recommendations were deleted. Thus, the final guidelines 140 
comprise of 71 recommendations and 5 statements (Table 4). To support the recommendations, 141 
the ESPEN guideline office created evidence tables of relevant meta-analyses, systematic reviews 142 
and (R)CTs, all of which are available online as supplemental material to these guidelines. 143 
Table 4. Classification of the strength of consensus and results of the online and consensus 144 
conference voting. 145 
  Online Voting 
Consensus 
Conference 
Strong consensus Agreement of >90% of participants 61 R + 5 S 10 R 
Consensus Agreement of >75 - 90 % of participants 10 R 1 R 
Majority agreement Agreement of >50 - 75 % of participants 2 S* - 
No consensus Agreement of <50 % of participants - - 
Deleted  - 3 R** 
R = Recommendation; S = Statement 146 
* These two statements were converted into recommendations 147 
9 
** Two recommendations were deleted during the revision after the online voting, one recommendation was deleted 148 
during the consensus conference 149 
 150 
Search strategy 151 
The literature search was performed separately for each PICO question in March 2018. Pubmed, 152 
Embase and Cochrane databases were searched using the filters “human”, “adult” and “English”. 153 
Table 5 shows the search terms used for the PICO questions. The results were pre-screened based 154 
on the abstracts of articles. In addition to the above databases, websites from nutritional (nursing) 155 
societies in English speaking or bilingual countries including the English language were searched 156 
for practice guidelines. 157 
Table 5. Search strategy 158 
PICO question Search terms used in combination with “home parenteral nutrition”, 
“human” and “adult” 
1. What are the indications for 
HPN? 
2. What are the criteria for an 
effective HPN program? 
3. What are the criteria for a 
safe HPN program? 
 
"guidelines" 
"registries" 
"indications" 
"malignant" OR "cancer",  
" program" 
"organization and administration OR management" 
"multidisciplinary" AND "team" 
4. Which venous access device 
should be chosen 
5. Which infusion control 
devices should be used for 
HPN? 
"central venous catheter" OR "central venous access device" 
"peripherally AND inserted AND central AND catheters" 
"infusion pumps" 
6. Which should be the 
appropriate infusion line 
management?  
 
"central venous catheter related infection" 
"catheter-associated infection OR contamination OR sepsis OR complications 
OR occlusion" 
"catheter dressing OR ointment OR lock" 
"catheter hub" 
"skin antisepsis" 
"aseptic technique" 
"catheter exit site” 
"hand decontamination" 
10 
"swimming OR bathing OR showering" 
"sutureless device" 
"catheter securement" 
"administration set OR intravenous tubing" 
"gloves" 
"needleless connector OR device" 
"antiseptic barrier cap" 
"port needle" 
"pre-filled syringes" 
"taurolidine" 
 
7. Which nutritional admixture 
bag should be chosen  
8. What are the critical steps 
during the preparation of PN 
admixtures? 
9. How should PN admixture be 
delivered? 
10. What should be the HPN 
admixture time and rate of 
infusion? 
 
"admixture" 
"premade OR premixed OR multichambered OR ready to use OR “all in one" 
"compounded OR customized" 
"stability" 
“delivery" 
“infusion” 
"rate" 
"blood glucose" 
"glycaemia" 
11. How should patients on 
HPN be monitored? 
"monitoring" 
"follow-up" 
"tolerance" 
"complications" 
"quality of care" 
 
12. Which are the local and 
personnel preconditions for 
home parenteral nutrition? 
13. Which are the requirements 
for the hospital centers that 
care for HPN patients? 
14. Which are the requirements 
for the nutritional support 
team? 
15. How should emergencies be 
managed? 
16. How should travelling with 
HPN be organized? 
17. Which criteria should be 
used to monitor the safety of 
HPN program provision? 
"intestinal failure" 
"central venous catheter complications" 
"program" 
"organization and administration OR management" 
"multidisciplinary AND team" 
"emergency" 
"admission" 
"central venous catheters complications" 
"travel OR travelling" 
"quality of health care" 
"quality of care" 
159 
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1. Indications for HPN 160 
1. What are the indications for HPN? 161 
Recommendation 1 162 
HPN should be administered to those patients unable to meet their nutritional requirements via 163 
the oral and/or enteral route and who can be safely managed outside of the hospital. 164 
Grade of Recommendation: GPP – Strong consensus (95.8% agreement) 165 
Commentary 166 
Several guidelines and standards on HPN have been published [3-15]. PN is a life-saving therapy to 167 
those unable to meet their nutritional requirements by oral/enteral intake . Clearly, no 168 
randomized controlled trial (RCT) can be conducted to compare HPN with placebo to confirm the 169 
life-saving efficacy of HPN therapy in this condition [3]. Furthermore, no absolute 170 
contraindications exist to the use of PN. However, the presence of organ failures and metabolic 171 
diseases, such as heart failure, renal failure, type 1 diabetes, may be associated with reduced 172 
tolerance to PN and may require careful and specific adaptations of the HPN program to meet the 173 
patient’s specific clinical needs.  174 
Six guidelines and one expert opinion-based standard on HPN in this setting were compared in a 175 
systematic review [10]. Although the guidelines generally covered the same topics, substantial 176 
differences were observed among the recommendations. Most did not provide information on 177 
intravenous medication, metabolic bone disease and indications in patients with malignant 178 
disease. Moreover, grading discrepancies among various guidelines were found, as identical 179 
recommendations were often labeled with different grades. Thus, the present guideline updates 180 
the recommendations from previous guidelines and standards relating to the appropriateness and 181 
safety of HPN. Nutritional requirements in specific clinical conditions, as well as the diagnosis and 182 
12 
treatment of CVAD and metabolic complications are not addressed in the present guideline. 183 
Recommendations in previous ESPEN guidelines about the latter topics are still valid [3,4]. 184 
 185 
2. What are the criteria for effective HPN program ? 186 
Recommendation 2 187 
HPN should be prescribed as the primary and life-saving therapy for patients with transient-188 
reversible or permanent-irreversible CIF due to non-malignant disease 189 
Grade of Recommendation B – Strong consensus (94.7% agreement) 190 
Commentary 191 
CIF has been defined as a chronic “reduction of gut function below the minimum necessary for the 192 
absorption of macronutrients and/or water and electrolytes, such that intravenous 193 
supplementation is required to maintain health and/or growth”, in metabolically stable patients 194 
[2]. CIF can be due to either benign or malignant disease and may be reversible or irreversible [2].  195 
The underlying diseases and the mechanisms of CIF due to benign disease in adults have been 196 
described in a recent international ESPEN survey [21]. Crohn’s disease, mesenteric ischemia, 197 
surgical complications, chronic intestinal pseudo-obstruction and radiation enteritis were the main 198 
underlying diseases, accounting for around 75% of cases. Short bowel syndrome was the main 199 
mechanism (around two-thirds of cases), while the remaining 33% of cases were due to intestinal 200 
dysmotility, enterocutaneous fistulas, intestinal mechanical obstruction and extensive mucosal 201 
diseases [21]. 202 
HPN is the primary and life-saving therapy for CIF [4]. The outcome of patients on HPN for CIF due 203 
to benign disease has been reported in many single and multicenter retrospective studies [22-28] 204 
and by an ESPEN prospective five year follow up [29-31]. These studies demonstrated that: 205 
13 
weaning from HPN after one to two years of starting may occur in 20% to 50% of patients; the five 206 
year survival probability on HPN ranges from 70 to 80% depending on the underlying disease; CIF 207 
may be associated with life-threatening complications of either the underlying disease or HPN, the 208 
latter accounting for around 14% of total deaths (such as CVAD-related complications and 209 
intestinal failure associated liver disease); the outcome of patients in terms of reversibility, 210 
treatment-related morbidity and mortality, and survival probability is strongly dependent on care 211 
and support from an expert multidisciplinary nutrition support team (NST). 212 
In Europe, the prevalence of HPN for CIF due to benign disease has been estimated to range from 213 
five to 20 cases per million population [22], with the exception of Denmark, where 80 cases per 214 
million have been recently reported [26]. 215 
Recommendation 3 216 
HPN can be considered for patients with CIF due to malignant disease 217 
Grade of Recommendation 0 – Strong consensus (95.8% agreement) 218 
Recommendation 4 219 
HPN should be prescribed to prevent an earlier death from malnutrition in advanced cancer 220 
patients with CIF, if their life expectancy related to the cancer is expected to be longer than one 221 
to three months, even in those not undergoing active oncological treatment. 222 
Grade of Recommendation B - Consensus (90% agreement) 223 
Commentary 224 
A mean survival of around 48 days has been reported in patients with malignant obstruction 225 
receiving palliative care without artificial nutritional support [32]. International guidelines [15,33-226 
35] generally advocate the use of PN in patients with malignancy who have failed oral and enteral 227 
nutrition (EN) and who have an expected survival longer than one to three months, which is the 228 
14 
longest predictable survival in an individual unable to maintain adequate oral nutrition without 229 
artificial nutritional support.  230 
A meta-analysis by Naghibi et al. [36] reported that 45% of incurable cancer patients receiving 231 
HPN for malignant intestinal obstruction can survive more than three months. The median and 232 
mean survival length was found to be 83 days and 116 days, respectively (55% mortality at three 233 
months and 76% mortality at six months, respectively) [36]. These data are in keeping with those 234 
of a large prospective multinational case series of 414 patients on HPN, 67% of whom had 235 
intestinal obstruction, (median survival 91 days, 50% mortality three months and 77% mortality at 236 
six months) [37].  237 
The clinical challenge is to accurately identify those patients who are likely to survive long enough 238 
to benefit from HPN treatment. Recently, a nomogram has been developed from variables 239 
recognized as independent prognostic factors (Glasgow prognostic score, presence and site of 240 
metastases and Karnofsky performance status), aimed at estimating  the 3-, 6-months and overall 241 
survival of incurable aphagic cachectic cancer patients considered for HPN [38]. 242 
It is noteworthy that the authors of a recent Cochrane review [39] concluded that they were very 243 
uncertain whether total HPN improves length of life in people with malignant bowel obstruction, 244 
largely as a result of the lack of published evidence. However, the authors reached these 245 
conclusions after applying strict Cochrane methodology (allocation concealment, comparability of 246 
treatment groups, blinding of participant and personnel) when reviewing the literature; this 247 
approach may be appropriate for evaluating medication efficacy, but may be less applicable to 248 
assessing the  role of essential nutrition [40]. 249 
Six prospective studies [41-46] on HPN-dependent patients for ≥ 1 month showed a benefit on 250 
health related quality of life (QoL) measured by validated tools (EORTC QLQ-C30 or FACT-G, or TIQ). 251 
There are three RCT evaluating the impact of HPN in patients outcome [47-49], with the largest 252 
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[48,49] reporting an improvement in energy balance and, as-treated analysis, prolonged survival, 253 
increased body fat and a greater maximum exercise capacity. The most recent RCT [50] comparing 254 
the effects of 6-month HPN to ‘best nutritional care’ in cachectic gastrointestinal cancer patients 255 
reported that HPN maintained or increased fat-free mass and improved QoL. It is noteworthy that 256 
a group of experts has identified QoL as one of the most important outcome indicators of HPN in 257 
cancer patients [51]. 258 
Specific contraindications for HPN support in cancer patients include [33]: 259 
a) patients who are not adequately informed about the aims of HPN, of its limited benefits and 260 
potential complications 261 
b) patients who are not informed of their predicted prognosis, or of the possibility of 262 
changing/withdrawing the treatment when it becomes futile 263 
c) patients who are not sufficiently metabolically stable to be discharged home on PN 264 
Recommendation 5 265 
HPN can be considered for patients without intestinal failure who are not able or do not want to 266 
meet their nutritional requirements via the oral/enteral route. The patient should be clearly 267 
informed about HPN benefits and risks. 268 
Grade of Recommendation GPP – Consensus (89.5% agreement) 269 
Commentary 270 
HPN surveys and registries report a percentage of cases who were not categorized as having either 271 
benign or malignant intestinal failure (Table 6) [52-57]. These may include patients needing 272 
artificial nutritional support who refused - or were not able to cope with - otherwise effective and 273 
clinically-recommended EN [58]. Such patients may have cancer and an indwelling CVAD for 274 
chemotherapy; alternatively, they may have dysphagia and elect not to have EN [59-61]. Since it is 275 
16 
difficult to deny nutritional support in clinical practice, HPN can sometimes be prescribed in these 276 
settings. Patients without CIF who are not able or do not want to meet their nutritional 277 
requirements via the oral/enteral route should be fully informed about the risks of PN therapy, 278 
which will likely be higher (including life-threatening risks related to HPN) than EN in this setting 279 
[3,4,58]. 280 
Table 6. Indications for HPN in adult patients in different countries according to data from 281 
national registries and surveys. 282 
National 
report, year 
(ref #) 
Total Patients 
(n.) 
Benign GI 
disease 
(%) 
Cancer on 
treatment 
(%) 
Cancer-
palliative 
(%) 
Others 
(%) 
SPAIN (SENPE 
Registry), 2016 
[52] 
256 44 10 25 Not specified, 21 
US (ASPEN 
Registry) , 
2011-2014 [53] 
1064 89 3 0.5 Malnutrition, 4.5 
Neurological swallowing disorder, 
0.1 
Not specified, 2.9 
 
UK (BANS 
report) 2015 
[54] 
1144 81.5 18.5 Indications for HPN in the total 
cohort: 
- Short bowel, 47 
- Fistula, 8 
- Malabsorption, 20 
- GI obstruction, 10 
- DR-Malnutrition, 6% 
- Swallowing Disorder. or 
Anorexia, 1 
- Others, 8 
ITALY (SINPE 
survey), 2012 
[55,56] 
46.1 
(/10
6
 
inhabitants) 
20 61 Neurological disease, 12% 
Not specified, 7 
CANADA (CNS 
Registry), 
2011-2014 [57] 
187 66 34  
GI, gastrointestinal; DR, disease-related 283 
 284 
 285 
 286 
 287 
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3. What are the criteria for a safe HPN program? 288 
Statement 1 289 
For a safe HPN program, the patient and/or the patient’s legal representative have to give fully 290 
informed consent to the treatment proposed. 291 
Strong consensus (95.7% agreement) 292 
Statement 2 293 
For a safe HPN program, the patient has to be sufficiently metabolically stable outside the acute 294 
hospital setting. 295 
Strong consensus (91.3% agreement) 296 
Statement 3 297 
For a safe HPN program, the patient’s home environment has to be adequate to safely deliver 298 
the therapy proposed. 299 
Strong consensus (95.7% agreement) 300 
Statement 4 301 
For a safe HPN program, the patient and/or the caregiver has to be able to understand and 302 
perform the required procedures for the safe administration of therapy. 303 
Strong consensus (95.7% agreement) 304 
 305 
Recommendation 6 306 
The patient and/or the caregiver should be trained by a NST to safely infuse the PN with 307 
appropriate monitoring and prompt recognition of any complications. 308 
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Grade of Recommendation GPP – Strong consensus (100% agreement) 309 
Recommendation 7 310 
The prescribed nutritional admixture and ancillaries required for safe and effective therapy 311 
should be delivered by an experienced/certified health care provider. 312 
Grade of Recommendation GPP – Strong consensus (95.7% agreement) 313 
Recommendation 8 314 
The NST should provide appropriate monitoring and treatment for routine and/or emergency 315 
care, with appropriate contact details provided to the patient 24 hours per day, seven days per 316 
week. 317 
Grade of Recommendation GPP – Strong consensus (100% agreement) 318 
Commentary 319 
HPN is a complex, life-saving therapy that may result in serious harm if not properly prescribed, 320 
prepared and administered. The aims of an HPN program include provision of evidence-based 321 
therapy, prevention of HPN-related complications such as catheter-related bloodstream infection 322 
(CRBSI) and metabolic complications, as well as ensuring QoL is maximized [3,4]. The HPN program 323 
shall provide an individualized, safe, effective and appropriate nutrition support plan at discharge 324 
from hospital which should then be supervised and evaluated on a regular basis in the community 325 
[62,63].  326 
Previous guidelines and standards recommend that prescription, implementation and monitoring 327 
of an individualized HPN program shall be managed by a NST in centers with HPN management 328 
expertise [3,10,51,64-74]. Patients managed by such a dedicated patient-centered NST have better 329 
outcomes and possible lower overall costs of care [22,64].  330 
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The overall care plan includes a variety of pre-discharge and post-hospital care assessments that 331 
require coordination between several heath-professionals and care providers within and outside 332 
the hospital (Table 7). In addition, besides involvement of the key-members of a NST (physician, 333 
dietician, nurse, pharmacist), specific patients will require input from physiotherapy, psychology 334 
and occupational therapy colleagues [3,67-70]. Communication with the caregivers at home 335 
(especially the home care nurse) and in the hospital seems to be a key-factor for patients [62,70]. 336 
An experienced and certified health care provider is also required for the appropriate delivery of 337 
nutritional admixture and ancillaries to patient’s home.  The ‘adequate’ metabolic and clinical 338 
stability of a patient can be assessed by vital parameters, energy, protein, fluid and electrolyte 339 
balances and glycemic control; here, the  where term adequate means no immediate risk of acute 340 
imbalance after hospital discharge.     341 
If the patient can achieve a stable HPN regimen and his/her overall clinical condition is acceptable, 342 
an education program for patients and/or caregivers should be initiated to teach correct and 343 
proper HPN care.  344 
The home care environment should be assessed before the education program starts.  345 
Table 7. Items to be included in the assessment at patient discharged on HPN [63,74] 346 
____________________________________________________________________________ 347 
• Medical, physical, psychological and emotional suitability/stability of the patient 348 
• Stability of the PN regimen (dosage and admixture) 349 
• Level of home care and support required 350 
• Lifestyle/activities of daily living 351 
• Rehabilitative potential 352 
• Potential for QoL improvement 353 
• Potential for learning self-management of HPN (patient/caregivers) 354 
• Knowledge and experience of the home nursing team (if no self-management) 355 
• Basic home safety, facilities and general cleanliness instruction 356 
• Need for extra equipment (e. g. backpack, infusion pump, hospital bed, extra drip stand) 357 
• Home care provider of nutritional admixture, equipment and ancillaries  358 
• Reimbursement for bags, services and supplies 359 
• Around the clock (on-call) availability of an experienced home care provider 360 
• Post-discharge monitoring necessities/possibilities (including scheduled laboratory tests) 361 
• Medication prescription with administration details 362 
____________________________________________________________________________ 363 
364 
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2. CVAD and infusion pump 365 
4. Which CVAD should be chosen? 366 
Recommendation 9 367 
The choice of CVAD and the location of the exit site shall be made by an experienced HPN NST, 368 
as well as by the patient. 369 
Grade of Recommendation GPP – Strong consensus (100% agreement) 370 
Recommendation 10 371 
The exit site of the CVAD should be easily visualized and accessible for self-caring patients.  372 
Grade of Recommendation GPP – Strong consensus (100% agreement) 373 
Recommendation 11 374 
Tunneled CVAD or totally implanted CVADs shall be used for long-term HPN. 375 
Grade of Recommendation GPP – Strong consensus (90.9% agreement) 376 
Recommendation 12 377 
Access to the upper vena cava should be the first choice for CVAD placement, via the internal 378 
jugular vein or subclavian vein. 379 
Grade of Recommendation B – Strong consensus (100% agreement) 380 
Recommendation 13 381 
Right-sided access should be preferred to the left-sided approach to reduce the risk of 382 
thrombosis.  383 
Grade of Recommendation B – Strong consensus (95.2% agreement) 384 
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Recommendation 14 385 
The tip of the CVAD should be placed at the level of the right atrial-superior vena cava junction. 386 
Grade of Recommendation B – Strong consensus (100% agreement) 387 
Commentary 388 
The literature search did not add any new information relating to this question when compared to 389 
the previous ESPEN guideline for CIF in adults [4]. The process of choosing a CVAD for HPN must 390 
involve the patient and the NST, including the specific professional (e.g. anaesthetist, radiologist or 391 
surgeon) responsible for placing the CVAD [76,77]. The patient should be involved in choosing the 392 
location of the cutaneous exit site which should, or course, also facilitate  optimal self-care [78]. 393 
Proximity to wounds, prior exit sites, tracheotomies, stomas or fistulae should be avoided. 394 
Tunneled CVAD (such as Hickman, Broviac or Groshong) or totally implantable devices (port) are 395 
usually chosen for long-term HPN (>6 months). [3]. A single lumen CVAD is preferred, as infections 396 
have been reported to occur more frequently with multiple lumen CVAD [73,79,80]. 397 
The risk of venous  thrombosis is reduced with  right vs. left-sided CVAD insertion [81] and, 398 
regardless of the type of catheter used and the insertion side, when the CVAD tip is located at the 399 
superior vena cava-right atrium junction [81-83]. 400 
 401 
Recommendation 15 402 
Peripherally inserted central venous catheters (PICCs) can be used if the duration of HPN is 403 
estimated to be less than six months. 404 
Grade of Recommendation 0 – Strong consensus (100% agreement) 405 
Commentary 406 
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ESPEN and ASPEN guidelines [4,84] for CIF do not recommend PICCs for long-term HPN. However 407 
many series have reported successful use of PICCS for up to four years [53,85-93].  408 
The concern of long term PICC use relates to the putative risk of catheter-related vein thrombosis 409 
and CRBSI compared to tunneled CVADs. A study comparing PICCs with other CVADs in long-term 410 
HPN found no difference in the CRBSI rate, a higher frequency of catheter removal because of 411 
venous-thrombosis and a shorter time between catheter insertion and the first complication in the 412 
PICC cohort [90]. A meta-analysis of comparative studies showed a lower rate of CRBSI in HPN 413 
patients using PICCs; however, no difference between PICC and tunneled CVADs was observed 414 
when the single-arm studies were analyzed [94]. 415 
In summary:  416 
a) better description of the reasons for placement and outcomes of  long-term PICC use in routine 417 
clinical practice is required  418 
b) PICCs seem to be associated with a lower risk of CRBSI and a possible higher risk of catheter-419 
related venous thrombosis;  420 
c) the time to the occurrence of the first catheter-related complication seems to be shorter with 421 
PICCs. 422 
 423 
424 
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5. Which infusion control devices should be used for HPN? 425 
Recommendation 16 426 
HPN should be administered using an infusion pump for safety and efficacy reasons. 427 
Grade of Recommendation GPP – Strong consensus (91.3% agreement) 428 
Recommendation 17 429 
In exceptional circumstances a flow regulator can be temporarily used for HPN; administration 430 
sets with only a roller clamp should not be used. 431 
Grade of Recommendation GPP – Strong consensus (100% agreement) 432 
Commentary 433 
The introduction of infusion pumps has been one of the major technologic advances for the safe 434 
administration of PN [95]. An infusion pump is a medical device that delivers fluids, such as 435 
nutrients and medications, into a patient’s body in controlled amounts [96]. The use of an 436 
electronic (ambulatory) infusion pump with compatible delivery sets is considered as good 437 
practice [6,97,98]. Because of the (large) fluid volume, the hypertonicity of the PN admixture and 438 
the amount of glucose and potassium delivered, rapid administration or ‘free flow’ can potentially 439 
cause serious harm [98].
 
 440 
It is therefore strongly recommended to use this device whenever possible to manage and 441 
monitor the delivery of HPN [3,4,6,13,51,99]. The characteristics of a safe and effective infusion 442 
pump for HPN are described in Table 8. 443 
 444 
 445 
 446 
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Table 8. Necessary features for an HPN infusion pump [4,6,96,98] 447 
____________________________________________________________________________ 448 
• Easy to clean (splash-proof)  449 
• Operating silently 450 
• User friendly interface (display/keyboard) 451 
• Portability: it should maximize patient’s mobility (e.g. possibility to carry it in a backpack together with the 452 
PN-bag) 453 
• Availability of a variety of pump-compatible sets with different line lengths 454 
• Rechargeable battery pack(s) with several hours operating time  455 
• Safety features: 456 
o audible and visual alarms 457 
o self-test at power-up 458 
o upstream and downstream occlusion alarms 459 
o anti-free flow control 460 
• Easy to use instructions  461 
o Safe operation 462 
o Alarm silencing, modification, disabling 463 
o Programmable mode options that include ramp-up/ramp-down and continuous infusion modes 464 
o Option to “lock out” those infusion modes not required and control the panel lock to prevent 465 
accidental or child tampering 466 
• Wireless interface (optional): 467 
o Infusion parameters remotely controlled 468 
o Pre-warnings or warnings on mobile phones 469 
• Service and maintenance contract provided, with regular testing of proper functioning 470 
____________________________________________________________________________ 471 
 472 
Recommendation 18 473 
A portable pump can improve the patient’s QoL when compared to stationary pumps. 474 
Grade of Recommendation 0 – Strong consensus (95.7% agreement) 475 
Commentary 476 
Two studies on the use of portable infusion pumps found that the ambulatory pump enabled HPN 477 
patients to gain independence [100,101]. Benefits included maintaining desired flow, low noise, 478 
long battery life as well as increased probability of social and working rehabilitation and of good 479 
QoL. If an ambulatory pump is not available (or appropriate because of the patient's condition), a 480 
standard volumetric pump with an intravenous stand is an alternative [4]. 481 
 482 
 483 
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3. Infusion line and catheter site care  484 
6. Which should be the appropriate infusion line management?   485 
Recommendation 19 486 
Either a sterile gauze or sterile, transparent, semipermeable dressing should be used to cover 487 
the CVAD exit site. 488 
Grade of Recommendation B – Strong consensus (90.9% agreement) 489 
Recommendation 20 490 
When transparent dressings are used on tunneled or implanted CVAD exit sites, they can be 491 
replaced no more than once per week (unless the dressing is soiled or loose). 492 
Grade of Recommendation 0 – Strong consensus (95.5% agreement) 493 
Recommendation 21 494 
A tunneled and cuffed CVAD with a well healed exit site might not require dressing to prevent 495 
dislodgement. 496 
Grade of Recommendation GPP confirmed – Strong consensus (100% agreement) 497 
Commentary 498 
The purpose of a dressing is to secure the  CVAD, as well as providing barrier protection from 499 
microbial colonization and infection. Different kinds of dressings can be used for protecting the 500 
CVAD site, including (semi-permeable) transparent polyurethane dressings and gauze and tape. 501 
Transparent dressings permit continuous visual inspection of the CVAD site and require less 502 
frequent changes unless the dressing becomes damp, loose, or visibly soiled. If there is visible pus 503 
exuding from the exit or the site is bleeding, it is better to use a gauze dressing (may be replaced 504 
every two days or sooner) until the problem is resolved [73]. 505 
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A recent systematic review included eight studies with patients in adult bone marrow 506 
transplantation (n=101), hemodialysis (n=138), gastroenterological (n=72), adult ICU (n=21), 507 
pediatric and adult oncology units (n=98) and general wards (n=76) and reported that there was 508 
no clear difference between gauze and tape and polyurethane dressings on the incidence of CRBSI. 509 
All included studies had a high risk of performance bias and were of low quality evidence [102]. A 510 
previous systematic review came to the same conclusion but the quality of the included studies 511 
was also low with small sample sizes and underpowered studies comparing different types of 512 
dressings [103]. Finally, in an older systematic review, the use of transparent dressings on CVAD 513 
was significantly associated with an elevated relative risk of catheter tip infection (RR = 1.78; 95% 514 
CI, 1.38 to 2.30) compared with gauze dressings [104]. 515 
The frequency of dressing change also remains a question of some debate. In a multicenter study, 516 
399 bone marrow transplant patients with a tunneled CVAD (n = 230) were randomly allocated to 517 
receive CVAD polyurethane dressing changes at different time intervals (Group 1: every two or five 518 
days, Group 2: every five or ten days). There was no difference in the rate of local infection but 519 
more skin toxicity was reported in the group with shorter interval dressing changes [105]. 520 
Nevertheless, a recent systematic review concluded that there is currently inconclusive evidence 521 
as to whether longer intervals between CVAD dressing changes are associated with more or less 522 
CVAD-related infections [106].
  
523 
After the healing period (+/- 3 weeks), it remains unclear if a dressing is necessary [73]. The recent 524 
ESPGHAN/ESPEN/ESPR/CSPEN guideline for pediatric parenteral nutrition access states that a 525 
tunneled CVAD with a well-healed exit site does not require dressing to prevent dislodgement 526 
(GPP); however, in children it is useful to have CVADs looped and covered [107]. 527 
A dressing could also potentially act as a reservoir for pathogens. One study tested this hypothesis 528 
by removing the CVAD exit site (gauze) dressing. Seventy-eight individuals with cancer and newly 529 
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inserted CVADs, stratified for gender (37 men and 41 women) and transplant status, were 530 
recruited and randomly assigned to receive either a gauze dressing or no dressing, once their 531 
CVAD insertion site had healed (three weeks). There was no significant difference in CRBSI 532 
episodes (p = 0.28) or rehospitalization rates (p = 0.41) between the dressing and no-dressing 533 
group, but individuals in the dressing group developed CRBSI sooner (p = 0.02) than did individuals 534 
in the no-dressing group [108]. 535 
 536 
Recommendation 22 537 
Tubing to administer HPN should be replaced within 24 hours of initiating the infusion. 538 
Grade of Recommendation B – Strong consensus (100% agreement) 539 
Commentary 540 
PN is considered as a medium where several factors may influence microbial growth leading to 541 
CRBSI risk [109]. In a prospective, randomized study, an intention-to-treat analysis demonstrated a 542 
higher level of intravenous tubing (administration set) colonization in tubes changed every 4- to 7-543 
days vs. those only changed every 3-days; however, the two groups had a comparable rate of 544 
colonization when patients receiving PN (n = 84) were excluded from this study [110]. Another 545 
randomized trial specifically involving PN infusion, found that changing tubing every 4 days vs. 546 
every 2 days did not impact on hub contamination and CRBSI rates [111].
 
A Cochrane systematic 547 
review found: a) no evidence to demonstrate that CRBSI rate was affected by frequent changes of 548 
non-lipid containing tubing; b) some evidence suggesting that mortality increased within the 549 
neonatal population with infrequent giving set replacement. However, much of the evidence 550 
evaluated in this Cochrane review was derived from studies of low to moderate quality [112,113]. 551 
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Currently there is no evidence that it is safe to extend the period of administration sets that 552 
contain lipids beyond an interval of 24 hours and this is generally accepted as best practice 553 
[112,113].
. 
Furthermore, the Center for Disease Control and Prevention (CDC) consider PN as an 554 
independent risk factor for CRBSI and recommend infusion set replacement after 24 hours [73]. 555 
Given that HPN patients are very often on cyclic PN, infusion sets normally will be replaced every 556 
24 hours. 557 
 558 
Recommendation 23 559 
Strict aseptic technique for the care of home CVAD shall be maintained. 560 
Grade of Recommendation A – Strong consensus (100% agreement) 561 
Commentary 562 
A recent systematic review revealed that there is not enough evidence to confirm whether 563 
patients receiving PN are more at risk of developing CRBSI that those who did not receive PN 564 
therapy [114]. 
 
Nevertheless, CRBSI is a common complication in patients receiving HPN. In a study 565 
of 172 adult HPN patients, 94 CRBSIs were diagnosed on 238 CVADs. Previous catheterizations and 566 
the presence of an enterocutaneous stoma were significantly related with a higher infection risk 567 
[115]. In another study with HPN patients, 465 CRBSIs developed in 187 patients (18%) during the 568 
three years study period [116].  569 
Cotogni et al [117] reported that the incidence of CRBSIs is low (0.35/1000 catheter-days), 570 
particularly for PICCs (0/1000; P < .01 vs Hohn and tunneled catheters) and for ports (0.19/1000; P 571 
< .01 vs Hohn and P < .05 vs tunneled catheters)  572 
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A systematic review in adult patients receiving HPN showed an overall CRBSI ranged between 0.38 573 
and 4.58 episodes/1000 catheter days (median 1.31). Gram-positive bacteria of human skin flora 574 
caused more than half of infections [118].
 
575 
 576 
Recommendation 24 577 
Hand antisepsis and aseptic non-touch technique should be used when changing the dressing on 578 
CVADs. 579 
Grade of Recommendation GPP – Strong consensus (100% agreement) 580 
Commentary 581 
Hand antisepsis is the most important measure to prevent contamination. Using gloves does not 582 
obviate the need for hand antisepsis. Gloves can be used when contact with blood, body fluids, 583 
secretions and excretions can be anticipated. The CDC leaves the choice of using gloves to local or 584 
federal regulations, rules, or standards [73]. There is only indirect evidence demonstrating the use 585 
of non-sterile gloves is not inferior to sterile ones even in more invasive procedures such as minor 586 
skin excisions and outpatient cutaneous surgical procedures, [119,120]. 587 
 588 
Recommendation 25 589 
A 0.5 - 2% alcoholic chlorhexidine solution shall be used during dressing changes and skin 590 
antisepsis; if there is a contraindication to chlorhexidine, tincture of iodine, an iodophor, or 70% 591 
alcohol shall be used as an alternative. 592 
Grade of Recommendation A – Strong consensus (95.2% agreement) 593 
Commentary 594 
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There is a body of evidence that demonstrates that the incidence of CRBSI is significantly reduced 595 
in patients with CVAD who receive chlorhexidine gluconate versus povidone-iodine for insertion-596 
site skin disinfection [73,121-125]. This is also the reason why chlorhexidine is mentioned in most 597 
checklists for CVAD insertion [126] 598 
 599 
Recommendation 26 600 
Hand decontamination, either by washing hands with soap and water but preferably with 601 
alcohol-based hand rubs, should be performed immediately before and after accessing or 602 
dressing a CVAD. 603 
Grade of Recommendation B – Strong consensus (95.2% agreement) 604 
Commentary  605 
Hand decontamination is a key factor in the prevention of health-care related infections which 606 
includes CVAD-related infections [73]. Several products are available: alcohol-based 607 
decontamination, non-alcohol-based decontamination, antimicrobial/antiseptic hand-washes or 608 
agents or liquid soap and water. Before using a hand-rub solution, hands should be free from dirt 609 
and organic material. The solution must come into contact with all surfaces of the hand. The hands 610 
must be rubbed together vigorously, paying particular attention to the tips of the fingers, the 611 
thumbs and the areas between the fingers, until the solution has evaporated and the hands are 612 
dry. This should be done immediately before and after direct patient care or contact and after 613 
removal of any gloves [127]. 614 
Results from a systematic review supported the use of alcohol-based hand rubbing: it removed 615 
microorganisms effectively, required less time and irritated hands less often than did handwashing 616 
with soap or other antiseptic agents and water [128]. Furthermore, the availability of bedside 617 
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alcohol-based solutions increased compliance with hand hygiene among health care workers [128].
 
618 
Other randomized trials also favored the use of alcohol-based solutions [129,130].
 
619 
 620 
Recommendation 27 621 
A needle-free connector should be used to access intravenous tubing. 622 
Grade of Recommendation B – Strong consensus (100% agreement) 623 
Recommendation 28 624 
Needle-free systems with a split septum valve may be preferred over some mechanical valves 625 
due to increased risk of infection with mechanical valves. 626 
Grade of Recommendation 0 – Strong consensus (100% agreement) 627 
Commentary 628 
Needleless connectors are an easy access point for infusion connection. They were introduced and 629 
mandated to prevent needlestick injuries, reducing the risk of transmission of blood-borne 630 
infections to healthcare personnel [73]. In several studies, the use of needleless connectors 631 
appears to be effective. Compared to the use of standard caps or 3-way stopcocks, they can 632 
reduce internal microbial contamination and so the incidence of CRBSI, but they have to be 633 
properly disinfected [131-133].
 
 634 
The majority of needleless connectors fall into one of two categories; namely those with no 635 
moving internal parts (e.g. an external split septum) and connectors which moving internal 636 
components. Based on available data, split septum connectors should be preferentially used 637 
instead of mechanical valves [73,134].
 
The issue becomes more complicated when the risk of (tip) 638 
occlusion due to negative displacement or blood reflux is also taken into account, depending on 639 
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the type of connector used [135].
 
Needleless connectors have to be changed no more frequently 640 
than every 72 hours or according to manufacturers’ recommendations [73]. 641 
 642 
Recommendation 29 643 
Contamination risk shall be minimized by scrubbing the hub connectors (needleless connectors) 644 
with an appropriate antiseptic (alcoholic chlorhexidine preparation or alcohol 70%) and access it 645 
only with sterile devices. 646 
Grade of Recommendation A  – Strong consensus (100% agreement) 647 
Recommendation 30 648 
For passive disinfection of hub connectors (needleless devices) antiseptic barrier caps should be 649 
used. 650 
Grade of Recommendation B – Strong consensus (90.9% agreement) 651 
Commentary 652 
Needleless connectors are used on virtually all CVAD, providing an easy access point for infusion 653 
connection. Infection guidelines strongly recommend proper disinfection of access ports [136]. A 654 
systematic review revealed that the greatest risk for contamination of the CVAD after insertion 655 
was the needleless connector, with 33-45% contaminated, and compliance with disinfection was 656 
as low as 10%, but the optimal technique or disinfection time were not identified [137].
  
Another 657 
systematic review recommended scrubbing with chlorhexidine-alcohol for 15 seconds [138]. 658 
However, if the membranous septum of a needleless luer-activated connector is heavily 659 
contaminated, conventional disinfection with 70% alcohol does not reliably prevent entry of 660 
microorganisms [139]. Since compliance with a time-consuming manual disinfection process is low, 661 
the use of an antiseptic barrier cap (placed on a luer needleless connector), which cleans the 662 
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connection surface by continuous passive disinfection, was associated with a decrease in CRBSI 663 
[139,140]. 664 
 665 
Recommendation 31 666 
If HPN is delivered via an intravenous port, needles to access ports should be replaced at least 667 
once per week. 668 
Grade of Recommendation GPP – Strong consensus (100% agreement) 669 
Commentary 670 
An implanted intravenous port is a small device with direct access to a central vein, used to draw 671 
blood and give treatments, including intravenous fluids, drugs, blood transfusions and PN. The 672 
port is placed just underneath the skin, usually in the chest. A catheter is attached to a 673 
subcutaneous pocket (made of titanium) with the tip ending at the right atrial-superior vena cava 674 
junction. To gain access, a needle is inserted through the skin and the rubbery self-healing 675 
membrane of the port. The CDC guideline considers the timeframe to replace needles as an 676 
‘unresolved’ issue [73]. There is also a possible higher risk of colonization of administration sets 677 
with PN. On the other hand, one retrospective study demonstrated that weekly changing of exit-678 
site needles and transparent dressings on intravenous ports seems to be safe and cost-effective 679 
but, in this study, patients on PN had a significantly greater risk of developing an infection from 680 
Candida Species [141]. In a study with patients on continuous chemotherapy, needles were in 681 
place for an average of 28 days without adverse effect [142]. Because there is no clear evidence, 682 
we suggest replacing port needles at least once-a-week with the use of PN. This also gives the 683 
opportunity for some patients to safely take a bath or shower when the needle has been removed 684 
and replaced afterwards. 685 
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 686 
Recommendation 32 687 
The CVAD or CVAD site should not be submerged unprotected in water. 688 
Grade of Recommendation B – Strong consensus (95.2% agreement) 689 
Commentary 690 
A study in children suggested that swimming did not increase the risk of tunneled CVAD-related 691 
infections [143].
 
No firm recommendation could be made in a review of 45 articles and 16 692 
pediatric HPN programs regarding swimming and CVADs but the authors also reporteda fatal 693 
event immediately after swimming [144].
  
Using a closed-hub system and waterproof catheter hub 694 
connections significantly reduced the incidence of CRBSIs (particularly infections caused by gram-695 
negative pathogens) in another group of pediatric patients [145]. 696 
The CDC guidelines (recommendation B) allow showering if precautions can be taken to reduce 697 
the likelihood of introducing organisms into the catheter (e.g. if the catheter and connecting 698 
device are protected with an impermeable cover during the shower) [73].
 
The
 
699 
ESPGHAN/ESPEN/ESPR/CSPEN guideline for pediatric PN access allows swimming (GPP) when a 700 
water-resistant dressing is used to cover the whole catheter and, after swimming, the exit site 701 
should be cleaned and disinfected [107]. 702 
 703 
Recommendation 33 704 
Sodium chloride 0.9% instead of heparin should be used to lock long-term CVAD. 705 
Grade of Recommendation B  – Strong consensus (95.5% agreement) 706 
Commentary 707 
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Historically, heparin was the most commonly used catheter lock solution. However, a 708 
retrospective study [146], a randomized prospective study [147] and two systematic reviews 709 
[148,149] demonstrated that normal saline flushing is not inferior to heparin flushing regarding 710 
CVAD occlusion, reflux dysfunction and flow dysfunction. ASPEN guidelines state that “no 711 
recommendations can be made as to which flush solution should be used to maintain patency for 712 
HPN CVAD due to the lack of studies” [84]. 713 
For the primary prevention of CVAD-related venous thrombosis, ESPEN guidelines for CIF 714 
recommend insertion of the catheter using ultrasound guidance and placement of the tip at the 715 
superior vena cava-right atrium junction, suggest flushing CVAD with saline and do not 716 
recommend routine thromboprophylaxis with drugs (heparin, warfarin) [4]. ESPEN guidelines for 717 
CIF do not recommend heparin for the prevention of CRBSIs [4], because it promotes intraluminal 718 
biofilm formation and therefore potentially increases the risk of CRBSIs [150,151]. German 719 
guidelines give a GPP grade for their recommendation of using saline and a grade B for their 720 
recommendation of not using heparin [11]. A grade B recommendation for the use of saline 721 
instead of heparin to flush and lock the CVAD is appropriate, given that this approach does not 722 
increase the risk of CVAD occlusion and has a lower risk of biofilm formation in the CVAD lumen.  723 
Recommendation 34 724 
As an additional strategy to prevent CRBSIs, taurolidine locking should be used because of its 725 
favorable safety and cost profile. 726 
Grade of Recommendation B – Strong consensus (100% agreement) 727 
Commentary 728 
For the primary prevention of CRBSI, ESPEN guidelines for CIF [4]:  729 
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a) recommend education of staff and patients/caregivers; implementation of an adequate policy 730 
of hand washing and disinfection by patients and staff; handwashing and disinfection by patients 731 
and caregivers before touching CVAD as well as after CVAD care; disinfection of the hub connector 732 
every time it is accessed; use of tunneled single-lumen catheters whenever possible; use of 733 
chlorhexidine 2% for antisepsis of hands, CVAD exit site, stopcocks, catheter hubs and other 734 
sampling ports and regular change of IV administration sets. 735 
b) suggest performing site care, including catheter hub cleaning on at least a weekly basis; 736 
changing CVAD dressings at least once weekly; avoiding CVAD care immediately after changing or 737 
emptying ostomy appliances and disinfecting hands after ostomy care. 738 
c) do not recommend the use of in-line filters; routine replacement of CVADs; antibiotic 739 
prophylaxis and heparin lock.  740 
ESPEN guidelines for CIF were published in 2016. Since then, no additional relevant literature was 741 
found concerning the above recommendations, but two high quality double blinded RCTs 742 
[152,153] and one extensive retrospective analysis [154] have been published on antimicrobial 743 
CVAD locking with various taurolidine formulations, that have considerably changed the available 744 
body of evidence and the strength of recommendation about the use of taurolidine for the 745 
prevention of CRBSI. All studies were performed in the setting of HPN support for adult benign CIF. 746 
Tribler et al. investigated CVAD locking with taurolidine 1.4%-citrate-heparin in comparison to 747 
control (low-dose heparin 100 IE/mL) in a single center study in 41 high-risk Danish HPN patients 748 
who had been stratified according to their prior CRBSI incidence [151]. In 20 patients who received 749 
the taurolidine-containing formulation, no CRBSIs occurred in contrast to CRBSIs in 7 out of 21 750 
controls (incidence 1.0/1000 CVC days; p< 0.05). Costs in the taurolidine arm were lower because 751 
of fewer admission days related to CRBSI treatment. 752 
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Since locking with heparin solutions has been suspected of promoting CRBSI, Wouters et al. 753 
compared a pure taurolidine 2% lock to another control (saline 0.9%) in a multicenter trial [153]. 754 
Patients were stratified in a new catheter group and a pre-existing catheter group. Overall 102 755 
patients were analyzed. In the new catheter group, CRBSIs/1000 catheter days were significantly 756 
lower (0.29 vs 1.49) in the taurolidine arm while in patients who entered the trial with a pre-757 
existing catheter CRBSI rates were also lower in the taurolidine arm (0.39 vs 1.32; p>0.05 due to 758 
under-powering). Mean costs per patient were significantly lower for taurolidine. Drug-related 759 
adverse events were rare and generally mild.  760 
Wouters et al also retrospectively analyzed long-term complications and adverse events in adult 761 
HPN patients from a national referral center who all used taurolidine locks between 2006 and 762 
2017 [154]. In total, 270 HPN patients used taurolidine during 338.521 catheter days. CRBSIs, 763 
catheter related venous thrombosis and occlusions occurred at rates of 0.60, 0.28, and 0.12 events 764 
per 1000 catheter days, respectively. In 24 (9%) patients, mild to moderate adverse events 765 
resulted in discontinuation of taurolidine. A subsequent switch to 0.9% saline resulted in an 766 
increased CRBSI rate (adjusted rate ratio 4.01, P = 0.02). Several risk factors were identified for 767 
CRBSIs (including lower age and increased infusion frequency), thrombosis (site of vein insertion), 768 
and occlusions (type of access device). 769 
 770 
Recommendation 35 771 
If a PICC is used for HPN, a sutureless device should be used to reduce the risk of infection. 772 
Grade of Recommendation B  – Strong consensus (100% agreement) 773 
38 
Recommendation 36 774 
For the securement of medium– to long-term PICCs (> 1 month) a subcutaneously anchored 775 
stabilization device can be used to prevent migration and save time during dressing change. 776 
Grade of Recommendation 0 – Strong consensus (100% agreement) 777 
Commentary 778 
A prospective study with 254 HPN patients revealed that use of sutureless devices for CVAD 779 
securement decreased the risk of CRBSI and dislocation (p < 0.001) [117].
 
A multiple treatment 780 
meta-analysis found that sutureless securement devices were as likely to be the most effective at 781 
reducing the incidence of CRBSI but the quality evidence was low [102].
 
For the securement of 782 
medium- to long-term PICCs, a subcutaneously anchored stabilization device can be used; it seems 783 
safe and cost-effective [155]. In the UK, the National Institute for Health and Care Excellence 784 
(NICE) recommends the adoption of this device (SecurAcath) for securing PICCs within the National 785 
Health Service in England [156]. Another study demonstrated that the use of SecurAcath saved 786 
time during dressing change compared with an alternative securement device (Statlock) but 787 
training on correct placement and removal was critical to minimize pain [157]. Besides sparing 788 
time during dressing change, it also can prevent migration of the PICC [158].
 
789 
 790 
Recommendation 37 791 
In multilumen catheters, a dedicated lumen should be used for PN infusion. 792 
Grade of Recommendation GPP – Strong consensus (95.5% agreement) 793 
Commentary  794 
39 
A previous ESPEN guideline recommended use of a single-lumen CVAD or of a dedicated lumen on 795 
a multilumen CVAD for PN administration [9]. The CDC guidelines gave no recommendation 796 
regarding the use of a dedicated lumen for PN [73]. Recently, Australian authors reviewed the 797 
available literature for comparative rates of CRBSIs in patients who received their PN in any health 798 
setting through a dedicated lumen compared with those who had PN administered through 799 
multilumen CVADs from 2286 records that were identified through database searching; they found 800 
only two studies that fit inclusion criteria in a qualitative synthesis [159]. These studies included 801 
650 patients with 1349 CVADs showing an equal distribution of CRBSIs between groups [159]. This 802 
lack of evidence for the use of a dedicated lumen to reduce infections most likely resulted from 803 
the poor way study results were reported with a high risk of bias, indicating the need for well-804 
powered high-quality research in this field. Therefore, the panel of the present guideline strongly 805 
agreed to confirm the recommendation made by the earlier ESPEN guidelines [9] 806 
 807 
Recommendation 38 808 
Routine drawing of blood samples from CVAD should be avoided if possible due to an increased 809 
risk of complications.   810 
Grade of Recommendation B – Strong consensus (95.2% agreement) 811 
Commentary 812 
When risk factors for CRBSI occurrence were retrospectively studied in 125 adults who received 813 
HPN by reviewing medical records from a national home care pharmacy in patients who used HPN 814 
at least twice weekly for > 2 years between 2006 and 2011, it was found in adults (331 CVADs, 815 
CRBSI rate 0.35/1000 catheter days) using univariate analysis that the use of subcutaneous 816 
infusion ports instead of tunneled catheters (p = 0.001), multiple lumen catheters (p = 0.001), 817 
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increased frequency of lipid emulsion infusion (p = 0.001), obtaining blood from the CVC (p < 818 
0.001), and infusion of non-PN medications via the CVC (p < 0.001), were significant risk factors for 819 
CRBSI occurrence [160]. 820 
Although high quality studies in the field of (H)PN are lacking, indirect evidence from a 821 
retrospective multivariate analysis of 452 totally implantable vascular devices in French cystic 822 
fibrosis patients that were used for administration of antibiotics, showed that removal, either due 823 
to obstruction (21%), infection (9%), septicemia (7%) or vascular thrombosis (5%), could be linked, 824 
apart from the CVC material (polyurethane vs silicone), to their routine use for blood sampling 825 
(versus never) [161]. 826 
 827 
4. Nutritional admixtures  828 
7. Which nutritional PN admixture bag should be chosen? 829 
Statement 5 830 
The HPN-admixture shall meet the patient’s requirement. 831 
Strong consensus (95.7% agreement) 832 
Recommendation 39 833 
Either commercially available ready-to-use admixtures or customized and tailored to the 834 
individual patient’s requirements admixtures can be used for HPN. 835 
Grade of Recommendation GPP – Strong consensus (95.7% agreement) 836 
Recommendation 40 837 
Customized and tailored HPN admixtures can be prepared either by individual compounding or 838 
by ready-to-use prepared and adapted commercial multi-chamber bags, according to the 839 
41 
manufacturer instructions and using aseptic admixture technique preferably in a laminar flow 840 
cabinet.  841 
Grade of Recommendation GPP – Strong consensus (100% agreement) 842 
Commentary 843 
The PN admixture provided for HPN should meet the individual patient’s requirements [3,4]. PN 844 
admixtures can be compounded in single bags, dual chamber bags or three in one/all-in-one (AIO) 845 
bags (these contain separate compartments for lipid emulsion/glucose/amino acids to be opened 846 
and mixed before infusion). Vitamins and trace elements can be added prior to infusion in the 847 
home setting, if appropriate compatibility and stability [3,4]. Dual and three chamber bags have 848 
advantages for HPN patients as they have a longer shelf life. Some AIO bags do not require 849 
refrigeration, which provides advantages for HPN patients while travelling. Stability is also 850 
markedly prolonged by refrigeration that requires a dedicated refrigerator for HPN storage [4]. 851 
The clinical advantages or disadvantages of individually compounded (“tailored” or “customized”) 852 
PN admixture in comparison with commercially available ready-to-use (“premade” or “premixed”) 853 
PN admixture adapted to the patient’s requirements has been addressed by previous guidelines, 854 
but published data did not support definitive recommendations. ESPEN guidelines do not address 855 
whether commercial ready to use bags (with or without additions) have any advantages over 856 
customized bags in the home setting [3,4]. ASPEN clinical guidelines state that commercial ready 857 
to use bags are considered as an available option for patients alongside customized PN 858 
formulations to best meet patients’ needs [162] However, this was based on literature comparing 859 
different types of bags in the hospital inpatient setting and not at home. The guideline also states 860 
that an evaluation of clinical outcomes, safety and cost should be considered before making the 861 
final determination. However, they highlight that most of the controlled clinical trials do not 862 
directly compare the use of commercial ready-to-use bags with customized PN systems for patient 863 
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outcomes, efficacy or safety and focus instead on evaluations following conversion from one 864 
delivery approach to another system [162]. German guidelines advocate the use of "all-in-one 865 
nutrient mixtures" and advise that multi-bottle systems should not be used because of increased 866 
risks and more difficult handling [11,163].  867 
The literature search for this guideline provided eleven articles that were considered to have some 868 
relevance to the question of comparison of commercial ready-to-use and customized PN 869 
admixture in non-critically ill patients [164-174]. Only one of the eleven articles, a conference 870 
abstract, compared different types of PN bags in the homecare setting, with all other articles 871 
evaluating the use of PN in hospital inpatients [164]. The results suggested that customized PN 872 
may be associated with a lower microbiological risk than commercial ready-to-use bags for 873 
patients with CIF; however, differences were not-statistically significant and this paper has not 874 
been published in full [164]. There were no studies found that compared commercial ready-to-use 875 
and customized PN in relation to clinical outcome or cost in HPN patients. There are no data on 876 
the use of different nutritional admixtures for people with CIF as result of benign vs. malignant 877 
disease. 878 
The results of the studies comparing commercial ready-to-use and customized PN in hospital 879 
inpatients may have some relevance for further studies in HPN patients. A number of studies in 880 
the hospital setting demonstrated that commercial ready-to-use PN is cheaper than customized 881 
PN; this may be due to lower acquisition costs, reduced preparation time and avoidance of costs 882 
associated with the development of CRBSI [165-169]. A retrospective study of in-hospital PN found 883 
that adding supplements to multi-chamber PN bags on the hospital ward increased blood stream 884 
infection risk [170], although this has not been confirmed in other studies [171]. Studies evaluating 885 
ready-to-use and customized PN in hospital highlight that the commercial ready-to-use PN may 886 
not suitable for all patients [166,172,173]. A recent systematic review comparing pharmacy 887 
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compounded PN bags and multi-bottle systems for in-patients noted that methodological factors 888 
limited evidence quality and highlighted the need for more prospective studies [174].
 
889 
Given the paucity of data in the HPN setting, further studies are clearly needed to investigate the 890 
cost implications, safety and clinical outcomes of using commercial ready-to-use PN-admixtures 891 
for patients with benign and malignant CIF.  892 
 893 
8. What are the critical steps during the preparation of PN admixtures? 894 
Recommendation 41 895 
Customized AIO admixture stability should be documented for the individual admixture based 896 
on checks by appropriate lab methods. 897 
Grade of Recommendation B – Strong consensus (100% agreement) 898 
Recommendation 42 899 
Customized AIO admixture stability shall not be extrapolated from the literature. 900 
Grade of Recommendation GPP – Strong consensus (95.2% agreement) 901 
Commentary 902 
AIO stability has to be documented for the individual admixture based on checks by appropriate 903 
lab methods. Literature extrapolation for stability is not adequate due to the complexities of the 904 
admixtures [11,175,176]. 905 
Electrolytes are prone to incompatibilities (precipitations, multi-valent cations and negative 906 
charged lipid emulsifier leading to emulsion destabilization). Their correct admixing into the 907 
appropriate macro-element component is crucial; in selected cases with a high calcium need, 908 
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organic instead of inorganic components might be preferable [176]. Easy to use and validated 909 
methods may be used to check for stability like for the Oil/Water stability of AIO admixtures [177]  910 
 911 
Recommendation 43 912 
AIO admixture shall be completed immediately before infusion by adding trace elements and 913 
vitamins according to stability and compatibility data. 914 
Grade of Recommendation GPP – Strong consensus (91.3% agreement) 915 
Commentary 916 
AIO admixture shall be completed by adding trace elements and vitamins in aseptic conditions 917 
according to stability and compatibility data. For structural/and or organizational reasons, the 918 
addition may also be performed immediately before infusion through appropriately trained 919 
persons. 920 
In order to prevent incompatibilities, including degradation of essential elements, vitamins may be 921 
preferably added by the end of the infusion cycle or as a bolus. Appropriate risk assessment for 922 
the Good Manufacturing Practice modalities but also the extent of standardization have to be 923 
addressed [11,178,179]. 924 
 925 
Recommendation 44 926 
Drug admixing into AIO admixture shall be avoided, unless specific pharmaceutical data are 927 
available to document compatibilities and stability of the AIO.  928 
Grade of Recommendation GPP – Strong consensus (100% agreement) 929 
Commentary 930 
45 
AIO admixtures show a high potential of drug interactions leading to incompatibilities or stability 931 
issues. They are normally not suited for drug admixing and, when necessary, the specific 932 
pharmaceutical data have to be provided and documented as this final product represents an 933 
individual drug product; the product performance and reliability after interaction with drugs is not 934 
covered by the manufacturer [177,180]. 935 
 936 
Recommendation 45 937 
AIO admixtures shall be labelled for the individual patient indicating the composition (dose) of 938 
the individual components according to standards, the date, the patient’s name and indication 939 
for handling such as storage, admixes to be made, infusion rate.  940 
Grade of Recommendation GPP – Strong consensus (100% agreement) 941 
 942 
Commentary 943 
AIO admixtures have to be labelled for the individual patient. Labels shall indicate the patient’s 944 
name, the composition (dose) of the individual components according to standards, the date of 945 
manufacturing and expiring, instructions for handling like storage, admixes to be made, infusion 946 
rate, as well as avoidance of medication errors [178,180,181]. Specific pharmaceutical support 947 
within the NST is required and efficacious [182]. 948 
 949 
9. How should PN admixture be delivered? 950 
46 
Recommendation 46 951 
For customized AIO admixtures, the cold chain should be guaranteed during transport and at the 952 
patient’s home. 953 
Grade of Recommendation B – Strong consensus (100% agreement) 954 
Commentary 955 
Clearly, pharmaceutical safeguards must be applied for PN delivery, storage and administration at 956 
home throughout the patient’s therapy. For customized AIO PN admixtures, the cold chain has to 957 
be guaranteed [176]. 958 
 959 
10. What should be the HPN admixture time and rate of infusion? 960 
Recommendation 47 961 
The hanging time for an HPN-admixture should be no longer than 24 hours. 962 
Grade of Recommendation GPP – Strong consensus (100% agreement) 963 
Recommendation 48 964 
At the end of cyclic PN administration, the infusion rate can be reduced to avoid rebound 965 
hypoglycemia (e.g. half of the infusion rate over the last half an hour). 966 
Grade of Recommendation GPP – Strong consensus (93.8% agreement) 967 
Commentary 968 
The generally accepted maximum hanging time for a ready-to-use admixture are 24 hours. The 969 
giving set has to be changed upon each new PN dosing [11,176,179,180]. 970 
47 
At the end of a (cyclic) PN-infusion, the infusion rate has to be reduced to tamper insulin need and 971 
to avoid rebound hypoglycemia (e.g. half of the infusion rate over the last half an hour). Glucose 972 
administration determines the maximum rate of PN infusion rate: (max. 5-7 mg glucose/kg/min; 973 
corresponding to about a maximum of 200 g glucose over twelve hours in 70 kg adult [176,180] or 974 
3-6 g glucose/kg per day [3]. 975 
976 
48 
5. Program monitoring 977 
11. How should patients on HPN be monitored? 978 
Recommendation 49 979 
Patients receiving HPN shall be monitored at regular intervals, to review the indications, the 980 
efficacy and the risks of the treatment. 981 
Grade of Recommendation GPP – Strong consensus (100% agreement) 982 
Recommendation 50 983 
The time between reviews should be adapted to the patient, care setting and duration of 984 
nutrition support; intervals can increase as the patient is stabilized on nutrition support.  985 
Grade of Recommendation GPP – Strong consensus (100% agreement) 986 
Recommendation 51 987 
HPN monitoring should be carried out by the hospital NST in collaboration with experienced 988 
home care specialists, home care agencies and/or general practitioners. 989 
Grade of Recommendation GPP – Strong consensus (100% agreement) 990 
Recommendation 52 991 
Patients and/or caregivers can be trained to monitor nutritional status, fluid balance and the 992 
infusion catheter. 993 
Grade of Recommendation 0 – Strong consensus (95.7% agreement) 994 
Recommendation 53 995 
Monitoring should comprise of nutritional efficacy, tolerance of PN, patient/caregiver 996 
management of infusion catheter, QoL and quality of care (e.g. CRBSI rate, readmission rate etc.). 997 
49 
Grade of Recommendation GPP – Strong consensus (95.7% agreement) 998 
Recommendation 54 999 
In clinically stable patients on long-term HPN, body weight, body composition and hydration 1000 
status, energy and fluid balance and biochemistry (hemoglobin, ferritin, albumin, C-reactive 1001 
protein, electrolytes, venous blood gas analysis, kidney function, liver function and glucose) 1002 
should be measured at all the scheduled (e.g. every three to six months). 1003 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1004 
Recommendation 55 1005 
In patients on long-term HPN, clinical signs and symptoms as well as biochemical indexes of 1006 
vitamin and trace metal deficiency or toxicity should be evaluated at least once per year. 1007 
Grade of Recommendation GPP – Strong consensus (95.7% agreement) 1008 
Recommendation 56 1009 
In patients on long-term HPN, bone metabolism and bone mineral density should be evaluated 1010 
annually or in accordance with accepted standards (e.g. DXA at max. every 18 months). 1011 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1012 
Commentary  1013 
The purpose of monitoring is to “secure and improve QoL” of persons on HPN by assessing the 1014 
nutritional efficacy of the HPN program, preventing and timely diagnosing and treating HPN-1015 
related complications and measuring QoL and quality of care [3,4]. Evidence-based guidelines for 1016 
monitoring are not available due to the lack of published data [3-13]. Only one study has been 1017 
published reporting monitoring practices for HPN across Europe [16]. The results showed that the 1018 
majority of centers performed a 3-month monitoring interval for stable patients and emphasized 1019 
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that responsibility for monitoring should be assigned to a designated person on the hospital HPN 1020 
specialist NST [16]. Prospective studies of the impact of different monitoring regimens on 1021 
outcomes (including QoL) of HPN are warranted.  1022 
Monitoring of HPN patients should be carried out by an experienced hospital NST and by home 1023 
care specialists as well as by a home care agency with experience in HPN and should also involve 1024 
the general practitioner. Healthcare professionals should review the indications, route, risks, 1025 
benefits and goals of nutrition support at regular intervals. In long-term HPN, patients and 1026 
caregivers should be trained in self-monitoring of their nutritional status, fluid balance and 1027 
infusion catheter, as well as in recognizing early signs and symptoms of complications and 1028 
responding to adverse changes in both their well-being and management of their nutritional 1029 
delivery system. 1030 
Parameters to be monitored, frequency and setting of monitoring are indicated in Table 9. The 1031 
time between reviews depends on the patient, care setting, duration of nutrition support as well 1032 
as the expected speed with which the impairment of a parameter is likely to occur. Monitoring 1033 
should be more frequent during the early months of HPN, or if there is a change in the patient’s 1034 
clinical condition. Intervals may increase as the patient is stabilized on nutrition support. Fluid 1035 
balance requires the most frequent monitoring, especially in the first period after discharge and in 1036 
patients with short bowel syndrome with a high output stoma or with intestinal dysmotility with 1037 
recurrent episodes of vomiting. Frequent acute dehydration episodes are responsible for kidney 1038 
failure and re-hospitalization [183,184]. On the other hand, vitamin and trace metal deficiency 1039 
may take more time to develop and to present clinical signs and symptoms, so that a six to twelve 1040 
month interval of assessment is appropriate. However, monitoring of micronutrients is as 1041 
important as monitoring other parameters, especially in patients on long-term HPN and in those 1042 
who are undergoing intestinal rehabilitation and weaning from HPN. In the latter case, while 1043 
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intestinal rehabilitation is associated with maintenance of energy, protein, fluid and electrolyte 1044 
balance without PN support, this is not necessarily the case for micronutrient balance [4]. 1045 
Decreasing or totally stopping PN infusion decreases micronutrient supplementation, thus creating 1046 
a risk for deficiency [4]. 1047 
After hospital discharge, it is critical that the HPN NST has contact with patients and caregivers on 1048 
a regular basis, initially every few days, then weekly and eventually monthly as the patient gains 1049 
confidence. The clinician who is in contact should be prepared to clarify confusing issues and also 1050 
to follow weight, urine output, diarrhea or stoma output, temperatures before and within an hour 1051 
of starting the HPN infusion, and general health.  1052 
Healthcare professionals have identified incidence of CRBSI, incidence of rehospitalization and QoL 1053 
as the three major indicators of quality of care HPN patients with either a benign [71] or malignant 1054 
[51] underlying disease. Survival rate was also considered important when patients with benign 1055 
disease were considered [185]. 1056 
 1057 
Table 9. Parameters, frequency (after baseline assessment) and setting of monitoring on 1058 
patients on HPN.  1059 
Parameter Frequency Setting 
General condition 
Body temperature 
Daily if unstable, twice weekly to 
once a week if stable 
Nurse at home 
Patient and/or caregivers  
Body weight Daily if unstable, twice weekly to 
once a week if stable 
In the hospital (outpatient visit) 
Nurse at home 
Patient and/or caregivers 
Body mass index Monthly In the hospital (outpatient visit) 
Nurse at home 
Fluid balance 
- Urine output 
- Stoma output 
- Number or consistency of 
stools 
- Presence of edema 
The frequency and type of 
parameters will depend on 
etiology of CIF, and stability of 
patients 
In case of high stool output (end 
jejunostomy), the monitoring after 
the first discharge should be daily, 
then twice weekly to once a week 
when stable 
Nurse at home 
Patient and/or caregivers only in 
case of training program 
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Catheter cutaneous exit site 
 
Daily  Nurse at home 
Patient and/or caregivers only in 
case of training program 
Full count blood 
C-reactive protein 
Serum glucose 
Serum and urine electrolytes and 
minerals (Na, Cl, K, Mg, Ca and P) 
Serum Urea and Creatinine 
Serum bicarbonates 
Urine analysis 
The frequency and type of 
parameters will depend on 
etiology of the underlying 
condition requiring HPN and the 
stability of patients 
Weekly or monthly, then every 
three to four months when stable 
At home 
Verify at each visit 
 
Serum albumin and prealbumin Monthly, then every three to four 
months when stable 
At home 
Verify at each visit 
Serum liver function tests 
including INR  
Monthly, then every three to four 
months when stable  
At home 
Verify at each visit 
Liver ultrasound Yearly In hospital 
Serum Folate, vitamins B12, A and 
E 
Every six to twelve months Dosage at home or in the hospital  
Serum ferritin iron, Every three to six months Dosage at home or in the hospital 
Serum 25-OH Vitamin D Every six to twelve months Dosage at home or in the hospital 
Serum zinc, copper, selenium Every six to twelve months Dosage in the hospital 
Serum Manganese Yearly Dosage in the hospital 
Bone densitometry (DEXA) Every twelve to eighteen months  In the hospital 
1060 
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6. Management (nutrition support team, training, emergency, travelling) 1061 
12. Which are the local and personnel preconditions for HPN? 1062 
Recommendation 57 1063 
The suitability of the home care environment should be assessed and approved by the HPN 1064 
nursing team before starting HPN, wherever possible. 1065 
Grade of Recommendation GPP – Strong consensus (91.3% agreement) 1066 
Recommendation 58 1067 
A formal individualized HPN training program for the patient and/or caregiver and/or home care 1068 
nurses shall be performed, including catheter care, pump use and preventing, recognizing and 1069 
managing complications; training can be done in an in-patient setting or at the patient’s home. 1070 
Grade of Recommendation GPP – Strong consensus (91.3% agreement) 1071 
Commentary  1072 
The management of PN in the home care setting differs from hospitalized patients because there 1073 
is a shift in primary responsibility from health care professionals to patients and caregivers. The 1074 
general goals in the education process are promoting independence with the infusion, (self-) 1075 
monitoring of HPN, preventing complications and improving or maintaining QoL [3,4] (Table 10). 1076 
The HPN center NST plays a key role in the individualized decision-making process and guides all 1077 
the necessary measures or steps which have to be taken [3,10,51,64-74]. 1078 
Guidelines on core components for (catheter) infection control and prevention, considered as an 1079 
important outcome indicator in HPN patients, give strong recommendations about the provision 1080 
of education and training [72,73]. Besides preventing CRBSI and assessing QoL, the overall 1081 
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teaching program has many aspects to deal with and is very often driven by an experienced 1082 
(nutrition support) nurse who takes the lead and responsibility for this program [3,69]. 1083 
 1084 
Table 10. Content of a teaching program for patients/caregivers discharged on HPN [3,10, 63,74] 1085 
____________________________________________________________________________ 1086 
• Indication for HPN: short and/or long-term goals and HPN-regimen 1087 
• Issues around informed consent 1088 
• Role of the home care provider to provide parenteral formulations, equipment, supplies, and eventually 1089 
nursing care 1090 
• Determine learning abilities and readiness to self-management and self-monitoring 1091 
o If applicable: make a checklist for competencies achieved  1092 
• Reviewing evidence-based written policies and procedures complemented with oral instructions 1093 
• Home care environment 1094 
o General cleanliness (for example: Is there a clean area for aseptic/sterile procedures?) 1095 
o Presence of animals 1096 
o Basic home safety (telephone access, clean storage for supplies, dedicated refrigerator, toilet-bathroom, 1097 
sanitary water supply,…) 1098 
• Catheter care 1099 
o Principles of infection control and prevention (including aseptic techniques) 1100 
o Preventing, recognizing and managing catheter related complications 1101 
o Site care 1102 
• Storage, handling, inspection of admixtures (e.g. leaks, labels, precipitates, color), ancillaries and (medication) 1103 
supplies 1104 
• If applicable: 1105 
o Safe addition of vitamins, trace elements or other additives 1106 
o Safe administration of HPN  1107 
o Connecting and disconnecting IV tubing to the vascular access device 1108 
o Pre/post infusion flushing 1109 
o Periodically assessment of performance/compliance with aseptic techniques 1110 
• Pump use, programming, pump care and troubleshooting 1111 
• Preventing, recognizing and managing non-infectious related complications or problems 1112 
• Most common mistakes 1113 
• Available contact resources and post discharge support from the HPN center as well as the home care 1114 
provider 1115 
• Self HPN monitoring 1116 
• Concomitant drug therapy and administration mode (total regimen management) 1117 
____________________________________________________________________________ 1118 
 1119 
Training for HPN may be carried out in an in-patient setting or at patient’s home and may take 1120 
several days to weeks depending on patient skills, duration of HPN and underlying condition. 1121 
[3,4,74). A recent retrospective 5-year evaluation of CRBSI occurrence and CVC salvage outcomes 1122 
in adult patients requiring HPN managed at a national UK intestinal failure unit, demonstrated that 1123 
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by individual managing, patients can be educated at home which of course reduces hospital length 1124 
of stay and may be preferable for some patients [75]. Multiple education interventions are 1125 
possible including one-on-one counselling, teach-back method, written handouts, computer-1126 
assisted learning and interactive presentations. All these tools may not eliminate but reduce post 1127 
discharge helpline contacts provided by telephone, videoconference or patient portals [63,68,74]. 1128 
Multiple education interventions are available including methods such as one-on-one counselling, 1129 
written or printed materials, group meetings, demonstrations, videotapes, CDs/DVDs and internet 1130 
education [3,4]. HPN is a complex therapy that requires coordination of many health care 1131 
providers. The expertise of a NST is recommended to provide proper and patient-tailored 1132 
education or therapy. Self-management and preventing complications are important goals to 1133 
improve QoL and to avoid unnecessary costs to healthcare. 1134 
 1135 
13. Which are the requirements for the hospital centers that care for HPN patients? 1136 
Recommendation 59 1137 
Patients on HPN should be cared for by specialized, dedicated and a clearly identifiable hospital 1138 
unit, normally termed “HPN center or IF center or intestinal rehabilitation center”. 1139 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1140 
Recommendation 60 1141 
The HPN unit should have offices for outpatient visits and dedicated beds for patients who need 1142 
hospitalization. 1143 
Grade of Recommendation GPP – Strong consensus (91.3% agreement) 1144 
Commentary  1145 
The human resources as well as structural facilities are key features to optimize the HPN care. 1146 
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Specific organization and structural facilities for HPN management have been described by a 1147 
position statement of the British Intestinal Failure Alliance [12], that described five standards: Unit, 1148 
Team, Practice, Relationship with other internal and external units/stakeholders and outcome. 1149 
Key issues are the identification of the persons, structures and procedures responsible for the HPN 1150 
care process [4,12,13], such as:  1151 
• Professionals who coordinate and manage the different phases of HPN management 1152 
• Place of initial care (center of intestinal failure, gastroenterology, surgery, other) 1153 
• Place and methods of training programs (on hospital beds, in day hospital, at home) 1154 
• Pathways of care in case of complications (example: emergency room, direct access to 1155 
hospital beds, link with local hospitals of the patient residency) 1156 
• Place and procedures for CVAD positioning and managing of complications 1157 
Having access to dedicated hospital beds under the responsibility of the MDT is essential for initial 1158 
care as well as for managing of complications. These beds may be within an independent structure 1159 
of nutrition/intestinal failure or within a more general structure, such as department of 1160 
gastroenterology, oncology, surgery or other. Hospitalization is required to monitor patients 1161 
and/or evaluate intestinal function in order to better adapt treatments as well as to timely and 1162 
appropriately treat complications according to the NST procedures. 1163 
The HPN center needs to estimate the time that each professional has to dedicate to the single 1164 
patient, in order to define the number of human resources required for managing their total 1165 
number of HPN patients. 1166 
In conclusion, for better care and visibility for patients, healthcare providers and public authorities, 1167 
we recommend that departments dedicated to the care of these patients be recognized with 1168 
dedicated beds and resources. 1169 
57 
 1170 
14. What are the requirements of the NST? 1171 
Recommendation 61 1172 
All HPN patients should be cared for by a NST with experience in HPN management, 1173 
independent from the underlying disease leading to intestinal failure. 1174 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1175 
Recommendation 62 1176 
The NST consists of experts in HPN provision. This can include a physician, specialist nurses 1177 
(including in catheter, wound and stoma care), dietitians, pharmacists, social worker, 1178 
psychologist, as well as an appropriate practitioner with expertise in CVC placement. Surgeons 1179 
with expertise in intestinal failure should also be available for structured consultation.  1180 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1181 
Commentary  1182 
Because of its complex nature, current guidelines, including the recent ESPEN guideline on CIF, 1183 
agree that only experienced NST should provide HPN treatment [3-14]. The relevance of expertise 1184 
in this field has been shown previously in France where increased experience in HPN support had a 1185 
positive impact on patient survival [186]. To assure optimal outcomes, the team should develop an 1186 
individualized training and treatment plans based on standardized protocols. Notably, CRBSI rates, 1187 
which are considered a proxy for the quality of HPN support, even in high-risk patients such as 1188 
those with cancer, are the lowest in expert referral centers [64,65].  1189 
The appropriate composition and size of a NST that provides HPN care to some extent depends on 1190 
the number of patients under the team’s care, which mostly also relates to the patient volume and 1191 
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scope of the hospital [187]. Key tasks of this team include establishing (contra)-indications for HPN 1192 
support, development and implementation of individualized training and treatment programs, 1193 
treatment of complications (vascular access related, metabolic derangements) and organization of 1194 
home care [187].  1195 
Also, because of the associated complications of HPN treatment, including venous access-related 1196 
problems such as infections and occlusions, metabolic derangements, formulation and medication 1197 
compatibility issues that pertain to various specialties, the team that provides HPN support should 1198 
be multidisciplinary in nature and include physician specialists with a background in surgery and 1199 
gastroenterology, specialized nurses, dieticians and pharmacists [66,67]. In light of the profound 1200 
impact on personal and family life, psychologists and social workers should also form part of the 1201 
team. This latter issue was highlighted in studies showing that many HPN patients experience the 1202 
lack of attention for their psychosocial problems as a shortcoming [188,199].  1203 
Concerning patients with active cancer, it is important to realize that selecting patients suitable for 1204 
such a complex treatment as HPN support is challenging and discussion with the treating oncology 1205 
specialist in this setting seems prudent before HPN initiation [15].  1206 
Often forgotten, it is of key importance for patients that caregivers more close to the home, such 1207 
as the general practitioner and homecare nurses, although not direct team members, should be 1208 
kept informed of patients’ clinical course after discharge from hospital [62,63,68,70]. It has been 1209 
shown in adult HPN patients who were managed at a national UK referral center that under the 1210 
well-organized care of such an experienced team in close collaboration with home nurses, even a 1211 
delicate process such as patient education can take place at home, resulting in reduced hospital 1212 
length of stay and improved psychosocial wellbeing of both patients and their family [75]. 1213 
15. How should emergencies be managed? 1214 
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Recommendation 63 1215 
The NST for HPN/CIF shall have clear written pathways and protocols in place for the 1216 
management of patients with complications relating to HPN. 1217 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1218 
Recommendation 64 1219 
The NST for HPN/CIF shall provide patients and caregivers with written information relating to 1220 
the recognition and subsequent management of HPN-related complications, including details 1221 
(e.g. telephone number) of an appropriate NST member to contact in the case of an emergency, 1222 
available 24 hours per day. 1223 
Grade of Recommendation GPP – Strong consensus (91.3% agreement) 1224 
Recommendation 65 1225 
The NST for HPN/CIF shall disseminate clear protocols relating to the recognition, investigation 1226 
and initial management of HPN-related complications to hospital emergency departments, 1227 
where patients are likely to present; where appropriate and available, written protocols can also 1228 
be carried by the patient or accessed electronically via a secure web-portal. 1229 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1230 
Recommendation 66 1231 
When patients are admitted to hospital with HPN-related complications, their care shall be 1232 
delivered by the NST for HPN/CIF; if patients are admitted to a hospital where such expertise 1233 
does not exist, then clinical guidance should be provided by the NST for HPN/CIF, until the time 1234 
when the patient can be transferred to the HPN/CIF center, as required.  1235 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1236 
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Recommendation 67 1237 
Written protocols for the management of HPN-related complications shall be developed and 1238 
shared with the patient’s local hospital, if it is likely that the patient will be admitted first to that 1239 
hospital rather than to the HPN/CIF center in the event of an emergency; these should include 1240 
contact details for the NST for HPN/CIF to advise on treatment and/or possible transfer to the 1241 
HPN/CIF center. Where appropriate and available, written protocols can also be carried by the 1242 
patient or accessed electronically via a secure web-portal. 1243 
Grade of Recommendation GPP – Strong consensus (95.5% agreement) 1244 
Recommendation 68 1245 
Patients shall carry details relevant to their condition, and/or have access to a secure web-portal 1246 
containing relevant clinical information, when travelling away from home, in order to aid clinical 1247 
teams at other hospitals should emergency treatment be required. 1248 
Grade of Recommendation GPP – Strong consensus (100% agreement) 1249 
Recommendation 69 1250 
The NST for HPN/CIF shall ensure that patients, caregivers and general practitioners are aware 1251 
of the roles and responsibilities of the health care professionals involved in aspects of the 1252 
patient’s condition that are unrelated to HPN, including any complications relating to the 1253 
patient’s underlying disease and other non-IF related conditions. 1254 
Grade of Recommendation GPP  – Strong consensus (100% agreement) 1255 
Commentary  1256 
Minimal guidance and published literature exist to-date relating to pathways for the emergency 1257 
management of patients with complications relating to CIF. Such complications should be 1258 
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demarcated into those relating to HPN, those relating to the patient’s underlying disease leading 1259 
to CIF (including any underlying oncological condition) and those unrelated to CIF. The CIF team 1260 
should ensure that patients and caregivers are aware of the roles and responsibilities of the health 1261 
care professionals involved in each component of their condition. 1262 
There are no published studies that have systematically evaluated best practice for the delivery of 1263 
emergency care for patients with HPN-related complications, for patients with benign CIF, 1264 
malignant CIF or no-CIF scenarios. Two studies have demonstrated patient-education programs 1265 
aimed at minimizing hospital admissions for complications associated with CIF. A retrospective 1266 
study evaluated the implementation of a protocol to treat dehydration at home for HPN patients 1267 
by ordering additional intravenous fluids to be kept on hand and to focus patient education on the 1268 
symptoms of dehydration; this led to a greater than two-fold increase in the number of episodes 1269 
of dehydration identified and treated at home [184]. Implementation of a CVC self-management 1270 
education program using a quasi-experimental, sequential cohort design study of patients with 1271 
cancer led to a reduction in CVC-related complications and improved patients’ abilities to resolve 1272 
problems and adequately respond to CVC-related emergency situations by fostering greater self-1273 
care ability; however, this study was not limited to patients with CIF [190]. Two further studies 1274 
demonstrated that diagnosis and management of CRBSI can be enhanced using quality 1275 
improvement methodology. An emergency department quality improvement initiative reduced 1276 
the mean time to antibiotic administration for febrile children with IF by 50%. Interventions 1277 
included increasing provider knowledge of IF, streamlining order entry, providing individualized 1278 
feedback, and standardizing the triage process. However, there was no difference noted in the 1279 
total length of subsequent hospital and ICU stays [191]. Another quality improvement project in a 1280 
tertiary cancer center involving staff education and blood culture source label introduction 1281 
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improved CRBSI diagnosis from 36% to 88% in patients with a CVC; however, this study was also 1282 
not limited to patients with CIF [192]. 1283 
Established national and international guidelines clearly recommend that that CIF patients are 1284 
cared for by a NST with skills and experience in both CIF and HPN management [4]. The British 1285 
Intestinal Failure Alliance provide some guidelines on the emergency management of HPN-related 1286 
complications [12]. The NST should be responsible for the management of patients with 1287 
complications related to HPN, including CVC-related complications and intestinal failure-related 1288 
liver disease. This should include the emergency management of any HPN-related issues 24 hours 1289 
per day, seven days per week. Patients and carers must be provided with clear written information 1290 
relating to the recognition and management of HPN-related complications, including contact 1291 
details of the NST in case of any emergency. The NST should generate written protocols for the 1292 
management of HPN-related complications and, importantly, should have systems in-place such 1293 
that specialist advice from the NST is available at all times. Where patients cannot attend the CIF 1294 
center with emergency issues (for example, if distance and/or clinical need mandates immediate 1295 
care at a local hospital), the NST should ensure that shared cared-protocols have been 1296 
disseminated to local hospitals in advance and that the patient also has relevant details of their 1297 
condition available.  1298 
Patients and caregivers should be aware that the NST may not be responsible for all aspects of 1299 
their health, including the underlying disease leading to CIF. For example, patients with Crohn’s 1300 
disease may be under the care of a gastroenterologist at a local hospital for the monitoring and 1301 
management of IBD-related issues. Similarly, for patients with malignancy, oncology and/or 1302 
palliative care teams best manage emergencies relating to underlying disease. Thus, as soon as a 1303 
patient is established on HPN, he/she and his/her general practitioner should be made aware of 1304 
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the relevant roles and responsibilities of the health care professionals involved in aspects of the 1305 
patient’s condition that are unrelated to HPN [3,11,14]. 1306 
Patients can suffer from non-IF related conditions and these can be a significant cause of 1307 
morbidity and mortality (for example, cardiac disease, respiratory disease etc.). Care for these 1308 
conditions, including any emergency needs, should continue as for patients without CIF [3,11,14]. 1309 
It is important that the NST is informed immediately of any changes in these conditions, including 1310 
any alterations in medication for non-IF related problems, as well as any admissions to hospital. 1311 
 1312 
16. How should travelling with HPN be organized? 1313 
Recommendation 70 1314 
For a patient to travel safely, he/she shall receive a sufficient supply of PN and relevant 1315 
ancillaries during the journey and at the destination and the NST responsible for the patient’s 1316 
care shall endeavor to establish contact with a skilled NST at the patient’s destination, in case 1317 
medical support is required.  1318 
Grade of Recommendation GPP  – Strong consensus (100% agreement) 1319 
Commentary 1320 
Patients on long-term HPN may need to learn how to adjust to lifestyle events such as bathing, 1321 
showering, swimming, sports and travel [12]. Travelling with PN is an important factor for some 1322 
patients’ QoL [193,194] and independency [70,195]. However, none of the previous guidelines and 1323 
position papers addressed this topic and a literature search did not provide any new information 1324 
about this area in adults. So the recommendation and comments of the present guideline were 1325 
based on statements of patients’ representatives participating in the panel. 1326 
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Pre-travel planning is essential to ensure that the patients can meet their usual PN/IV fluid 1327 
requirements as well as to be able to perform PN-related procedures safely. The 1328 
patient/caregivers should discuss their travel plans with their healthcare professionals/NST to 1329 
ensure that they/their child are fit to travel. The doctor should issue a letter/medical certificate for 1330 
the patient/caregivers confirming that they are aware they are travelling, along with a brief 1331 
overview of their condition and need for PN. Medical cover/travel insurance should be arranged 1332 
prior to travelling to ensure that any medical treatment needed while travelling will be possible. 1333 
The patient/caregivers should ask about the potential and suitability of multi-chamber bags for 1334 
their trip instead of compounded PN if they would like to consider using them. The 1335 
patient/caregivers should investigate different power supplies/plugs prior to travelling to ensure 1336 
they can charge pumps and batteries. A spare infusion pump should be taken on all trips, 1337 
alternatively check the possibility of a replacement pump at the destination. Using 1338 
homecare/compounding services at the end destination should be investigated very early during 1339 
the planning period where reimbursement is possible and is available via different healthcare 1340 
systems. The patient/caregivers need to calculate the number of fluid bags (PN/IV fluids) and 1341 
ancillaries/medical supplies that they will need for their trip allowing for extra supplies. It is the 1342 
responsibility of the patient/caregivers to know the stability of the PN, how long compounded PN 1343 
can be safely stored in the dedicated PN boxes supplied by homecare companies/hospitals, before 1344 
it needs to be placed in a fridge. The patient/parents should plan for additional fluids for the 1345 
duration of travel, where high temperatures may be experienced, to ensure hydration is 1346 
maintained. All fluids and ancillaries/medical supplies must be appropriately packed to ensure safe 1347 
storage and stability both in terms of preventing damage and maintaining cold-chain temperatures, 1348 
where applicable. The type of accommodation should be carefully considered in advance, 1349 
especially where a fridge is required for the storage of compounded PN at 2
o
 – 8
o
C. In case of an 1350 
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emergency situation, a plan of action should be prepared beforehand and all important (doctor, 1351 
family) contact numbers should be easily accessible. All modes of transport are possible for PN, 1352 
travelling by plane will require more detailed planning. Attention to increased security checks 1353 
must be respected. Prior to travel, if any special arrangements need to be made - such as 1354 
additional space, extra baggage allowance, security approval – this must be arranged prior to 1355 
departure. All PN/IV fluid boxes and ancillary/medical supplies baggage should be clearly labelled 1356 
with a name, destination, date of travel and instructions not to open if cold-chain PN unless in the 1357 
presence of the patient/caregivers. Usual healthcare professionals should consider establishing 1358 
local medical support or a contact for the patient should medical support be required. 1359 
 1360 
17. Which criteria should be used to monitor the safety of HPN program provision? 1361 
Recommendation 71 1362 
Incidence of catheter-related infection, incidence of hospital readmission and QoL should be 1363 
used as criteria to assess the quality of care of HPN program. 1364 
Grade of Recommendation GPP  – Strong consensus (100% agreement) 1365 
Commentary  1366 
Three multicenter international studies have identified and ranked the interventions determined 1367 
to be essential for good quality of care (also called ‘key interventions’) [51,71,185]. Two studies 1368 
were based on the opinions of healthcare professionals with expertise on HPN and included either 1369 
benign or malignant CIF [51,71]. The third study evaluated the desired outcomes of patients with 1370 
CIF due to benign disease [70,185]. The two-round Delphi approach was used, which is a technique 1371 
that transforms opinion into group consensus, and the resulting set of most highly ranked key 1372 
interventions was then transformed into quality indicators [51,71,185]. 1373 
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The top three outcome indicators identified by healthcare professionals were incidence of CRBSI, 1374 
incidence of rehospitalizations and QoL for CIF due to either benign [71] or malignant [51] disease. 1375 
The top three desired outcomes of patients with benign CIF were incidence of CRBSI, survival rate, 1376 
and QoL on HPN [185].  1377 
The key interventions identified should be measured annually in current practice, along with 1378 
questionnaires on patients’ satisfaction, to identify and address any areas for further 1379 
improvement. [4].  1380 
According to the Donabedian paradigm [196], the outcome indicators should not be measured 1381 
alone. The Donabedian model provides a framework to assess the quality of care by working with 1382 
quality indicators related to structure, process and outcome of health care: ’structure’ refers to 1383 
general administrative standards of the organization and people providing care; ‘process’ refers to 1384 
the manner in which care is actually provided and administered; ‘outcome’ refers to a set of 1385 
expected or desirable results for patients [196]. Therefore, the outcome indicators reported 1386 
should be monitored along with the linked process as well as structure indicators which will help 1387 
to drive quality improvement. 1388 
1389 
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